Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLH8NDE
- Development stage
- Unknown
- Lead developer
- GL Pharm Tech
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
GLH8NDE is a small molecule eupatilin derivative being developed by GL Pharm Tech Corporation for the treatment of dry eye syndrome. Formulated as a 5% ophthalmic solution, the drug is intended to leverage the anti-inflammatory and cytoprotective properties of eupatilin to treat ocular surface disease. Clinical development has progressed through Phase 1 safety and pharmacokinetic studies in healthy volunteers and into Phase 2 trials to evaluate efficacy and safety in patients with dry eye disease. Phase 1 studies in healthy Korean and Caucasian volunteers demonstrated that the drug is rapidly absorbed and well-tolerated without significant systemic effects.
- Other names
- eupatilin derivative
Beyond the preview
Go deeper on GLH8NDE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLH8NDE.